NKX2-1 and cyclic hematopoiesis: While there is not a clear pathophysiological basis to corroborate this finding specifically in patients with NKX2-1-RD hypothyroidism, it prompts a crucial consideration for the management of CH cases, particularly those associated with NKX2-1 pathogenic variants or deletions.